2014 – Virobay completes $8 million Series B preferred stock financing more
2014 – Virobay announces the appointment of James Welch as Chief Financial Officer more
2014 – Virobay appoints Thomas J. Dietz, Ph.D. to the Virobay Board of Directors more
2013 – Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain more
2013 – Virobay and LEO Pharma initiate a Phase 1 Trial of VBY-891, a compound intended for oral treatment of psoriasis more
2012 – Virobay's Cathepsin S selected as one of the Top 10 Anti-Inflammatory/Autoimmune Projects to Watch more
2012 – LEO Pharma A/S has entered into a multi-million dollar collaboration with Virobay Inc. to develop an oral treatment for psoriasis more
2010 – Virobay closes Series B financing
December 5, 2012
"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive anti-inflammatory/autoimmune opportunities the industry has to offer," said David Cassak, Vice President, Content, Windhover Conferences, a division of Elsevier Business Intelligence.
"Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."
Link to presentation "Cathepsin S Inhibitors for the Treatment of Inflammatory Bowel Disease"
July 16, 2014
June 25, 2014
February 25, 2014
May 23, 2013
March 18, 2013
January 9, 2012
November 14, 2011
November 3, 2011